Aim
The aim of INTEGRATE IIa is to determine whether regorafenib160mg daily on day 1 to 21 of a 28-day cycle improves OS compared to placebo. The aim of INTEGRATE IIb is to determine whether regorafenib 90 mg daily on day 1 to 21 of a 28-day cycle in combination with nivolumab 240 mg every 2 weeks improves OS compared to investigator’s choice of chemotherapy in participants with AGOC who have progressed or were intolerant to two or more lines of chemotherapies including platinum and fluoropyrimidine based regimens. After 2 months, nivolumab can be given monthly at a dose of 480 mg.